• 文献检索
  • 文档翻译
  • 深度研究
  • 学术资讯
  • Suppr Zotero 插件Zotero 插件
  • 邀请有礼
  • 套餐&价格
  • 历史记录
应用&插件
Suppr Zotero 插件Zotero 插件浏览器插件Mac 客户端Windows 客户端微信小程序
定价
高级版会员购买积分包购买API积分包
服务
文献检索文档翻译深度研究API 文档MCP 服务
关于我们
关于 Suppr公司介绍联系我们用户协议隐私条款
关注我们

Suppr 超能文献

核心技术专利:CN118964589B侵权必究
粤ICP备2023148730 号-1Suppr @ 2026

文献检索

告别复杂PubMed语法,用中文像聊天一样搜索,搜遍4000万医学文献。AI智能推荐,让科研检索更轻松。

立即免费搜索

文件翻译

保留排版,准确专业,支持PDF/Word/PPT等文件格式,支持 12+语言互译。

免费翻译文档

深度研究

AI帮你快速写综述,25分钟生成高质量综述,智能提取关键信息,辅助科研写作。

立即免费体验

儿童和青少年精神病学中的药物监测,以提高精神药理学治疗的疗效和安全性。

Drug monitoring in child and adolescent psychiatry for improved efficacy and safety of psychopharmacotherapy.

机构信息

Department of Child and Adolescent Psychiatry/Psychotherapy, University of Ulm, Ulm, Germany.

出版信息

Child Adolesc Psychiatry Ment Health. 2009 Apr 9;3(1):14. doi: 10.1186/1753-2000-3-14.

DOI:10.1186/1753-2000-3-14
PMID:19358696
原文链接:https://pmc.ncbi.nlm.nih.gov/articles/PMC2674035/
Abstract

Most psychotropic drugs used in the treatment of children and adolescents are applied "off label" with a direct risk of under- or overdosing and a delayed risk of long-term side effects. The selection of doses in paediatric psychiatric patients requires a consideration of pharmacokinetic parameters and the development of central nervous system, and warrants specific studies in children and adolescents. Because these are lacking for most of the psychotropic drugs applied in the Child and Adolescent and Psychiatry, therapeutic drug monitoring (TDM) is a valid tool to optimise pharmacotherapy and to enable to adjust the dosage of drugs according to the characteristics of the individual patient. Multi-centre TDM studies enable the identification of age- and development-dependent therapeutic ranges of blood concentrations and facilitate a highly qualified standardized documentation in the child and adolescent health care system. In addition, they will provide data for future research on psychopharmacological treatment in children and adolescents, as a baseline for example for clinically relevant interactions with various co-medications. Therefore, a German-Austrian-Swiss "Competence Network on Therapeutic Drug Monitoring in Child and Adolescent Psychiatry" was founded 1 introducing a comprehensive internet data base for the collection of demographic, safety and efficacy data as well as blood concentrations of psychotropic drugs in children and adolescents.

摘要

大多数用于治疗儿童和青少年的精神药物都是“超适应证”使用的,这直接存在药物剂量过低或过高的风险,以及长期出现副作用的延迟风险。在儿科精神科患者中选择剂量时需要考虑药代动力学参数和中枢神经系统的发育,并需要在儿童和青少年中进行特定的研究。由于大多数应用于儿童和青少年精神病学的精神药物缺乏这些研究,治疗药物监测(TDM)是优化药物治疗的有效工具,并能够根据个体患者的特点调整药物剂量。多中心 TDM 研究能够确定与年龄和发育相关的血液浓度治疗范围,并促进儿童和青少年保健系统中高度合格的标准化记录。此外,它们将为未来儿童和青少年精神药理学治疗的研究提供数据,例如作为与各种合并药物的各种临床相关相互作用的基线。因此,成立了一个德奥瑞“儿童和青少年精神病学治疗药物监测能力网络”,引入了一个综合的互联网数据库,用于收集儿童和青少年精神药物的人口统计学、安全性和疗效数据以及血液浓度数据。

相似文献

1
Drug monitoring in child and adolescent psychiatry for improved efficacy and safety of psychopharmacotherapy.儿童和青少年精神病学中的药物监测,以提高精神药理学治疗的疗效和安全性。
Child Adolesc Psychiatry Ment Health. 2009 Apr 9;3(1):14. doi: 10.1186/1753-2000-3-14.
2
Therapeutic drug monitoring in child and adolescent psychiatry.儿童和青少年精神病学中的治疗药物监测。
Pharmacopsychiatry. 2011 Sep;44(6):249-53. doi: 10.1055/s-0031-1286291. Epub 2011 Sep 28.
3
[Therapeutic drug monitoring in child and adolescent psychiatry--practical recommendations].儿童及青少年精神病学中的治疗药物监测——实用建议
Z Kinder Jugendpsychiatr Psychother. 2006 Jan;34(1):5-13. doi: 10.1024/1422-4917.34.1.5.
4
The AGNP-TDM expert group consensus guidelines: therapeutic drug monitoring in psychiatry.AGNP-TDM专家组共识指南:精神科治疗药物监测
Pharmacopsychiatry. 2004 Nov;37(6):243-65. doi: 10.1055/s-2004-832687.
5
[Therapeutic drug monitoring to optimize psychopharmacotherapy in children and adolescents - Update and guidelines for practice].[治疗药物监测以优化儿童和青少年的精神药物治疗——最新进展与实践指南]
Z Kinder Jugendpsychiatr Psychother. 2021 Mar;50(2):133-152. doi: 10.1024/1422-4917/a000845.
6
Therapeutic drug monitoring as a measure of proactive pharmacovigilance in child and adolescent psychiatry.治疗药物监测作为儿童和青少年精神病学中主动药物警戒的一种措施。
Expert Opin Drug Saf. 2016 Nov;15(11):1477-1482. doi: 10.1080/14740338.2016.1225721. Epub 2016 Aug 26.
7
AGNP consensus guidelines for therapeutic drug monitoring in psychiatry: update 2011.AGNP 精神病治疗药物监测共识指南:2011 年更新版。
Pharmacopsychiatry. 2011 Sep;44(6):195-235.
8
Clinical utility of drug measurement and pharmacokinetics: therapeutic drug monitoring in psychiatry.药物测量与药代动力学的临床应用:精神科的治疗药物监测
Eur J Clin Pharmacol. 2008 Feb;64(2):159-66. doi: 10.1007/s00228-007-0430-1. Epub 2008 Jan 15.
9
[Prescription of psychotropic drugs in paediatry: approved indications and therapeutic perspectives].[儿科精神药物处方:批准的适应症和治疗前景]
Encephale. 2005 Jul-Aug;31(4 Pt 1):477-89. doi: 10.1016/s0013-7006(05)82409-1.
10
Therapeutic drug monitoring in neuropsychopharmacology: does it hold its promises?神经精神药理学中的治疗药物监测:它是否能兑现承诺?
Eur Arch Psychiatry Clin Neurosci. 2008 Mar;258 Suppl 1:21-7. doi: 10.1007/s00406-007-1005-y.

引用本文的文献

1
Serum Concentration-Dose Relationship and Modulation Factors in Children and Adolescents Treated with Fluvoxamine.氟伏沙明治疗儿童和青少年的血清浓度-剂量关系及调节因素
Pharmaceutics. 2024 Jun 6;16(6):772. doi: 10.3390/pharmaceutics16060772.
2
Therapeutic drug monitoring of atomoxetine in children and adolescents with attention-deficit/ hyperactivity disorder: a naturalistic study.阿托西汀在注意缺陷多动障碍儿童和青少年中的治疗药物监测:一项自然研究。
J Neural Transm (Vienna). 2022 Jul;129(7):945-959. doi: 10.1007/s00702-022-02483-8. Epub 2022 Apr 7.
3
Therapeutic drug monitoring in children and adolescents with schizophrenia and other psychotic disorders using risperidone.利培酮在儿童和青少年精神分裂症及其他精神障碍患者中的治疗药物监测。
J Neural Transm (Vienna). 2022 Jun;129(5-6):689-701. doi: 10.1007/s00702-022-02485-6. Epub 2022 Mar 18.
4
Audit of physical health monitoring in children and adolescents receiving antipsychotics in neurodevelopmental clinics in Northumberland.诺森伯兰郡神经发育诊所中接受抗精神病药物治疗的儿童和青少年的身体健康监测审计
World J Psychiatry. 2018 Mar 22;8(1):27-32. doi: 10.5498/wjp.v8.i1.27.
5
Relationship between clozapine dose, serum concentration, and clinical outcome in children and adolescents in clinical practice.临床实践中儿童和青少年氯氮平剂量、血清浓度与临床结局之间的关系。
J Neural Transm (Vienna). 2016 Aug;123(8):1021-31. doi: 10.1007/s00702-016-1573-y. Epub 2016 May 24.
6
Sampling time and indications appropriateness for therapeutically monitored drugs at a teaching university hospital in Oman.阿曼一所教学医院中治疗监测药物的采样时间及适应证适宜性
Saudi Pharm J. 2015 Sep;23(4):458-62. doi: 10.1016/j.jsps.2014.11.005. Epub 2014 Nov 24.
7
SENTIA: a systematic online monitoring registry for children and adolescents treated with antipsychotics.SENTIA:一个用于接受抗精神病药物治疗的儿童和青少年的系统性在线监测登记处。
Springerplus. 2014 Apr 14;3:187. doi: 10.1186/2193-1801-3-187. eCollection 2014.
8
Safety and pharmacokinetics of atypical antipsychotics in children and adolescents.儿童和青少年使用非典型抗精神病药物的安全性和药代动力学。
Paediatr Drugs. 2013 Jun;15(3):217-33. doi: 10.1007/s40272-013-0024-6.
9
Antidepressant exposure as a predictor of clinical outcomes in the Treatment of Resistant Depression in Adolescents (TORDIA) study.抗抑郁药暴露作为青少年难治性抑郁症治疗(TORDIA)研究中临床结局的预测因子。
J Clin Psychopharmacol. 2011 Feb;31(1):92-7. doi: 10.1097/JCP.0b013e318204b117.

本文引用的文献

1
Ethical issues in psychopharmacology of children and adolescents.儿童和青少年心理药理学中的伦理问题。
Curr Opin Psychiatry. 2008 Nov;21(6):598-605. doi: 10.1097/YCO.0b013e328314b776.
2
A three-country comparison of psychotropic medication prevalence in youth.三国青少年精神药物使用情况比较。
Child Adolesc Psychiatry Ment Health. 2008 Sep 25;2(1):26. doi: 10.1186/1753-2000-2-26.
3
Off-label psychopharmacologic prescribing for children: history supports close clinical monitoring.儿童非适应证精神药理学处方:历史支持密切临床监测。
Child Adolesc Psychiatry Ment Health. 2008 Sep 15;2(1):24. doi: 10.1186/1753-2000-2-24.
4
CYP2D6 phenotype prediction from genotype: which system is the best?基于基因型预测CYP2D6表型:哪种系统最佳?
Clin Pharmacol Ther. 2008 Feb;83(2):225-7. doi: 10.1038/sj.clpt.6100455.
5
Selective serotonin reuptake inhibitors (SSRIs) and routine specialist care with and without cognitive behaviour therapy in adolescents with major depression: randomised controlled trial.选择性5-羟色胺再摄取抑制剂(SSRIs)与针对重度抑郁症青少年的常规专科护理(有无认知行为疗法):随机对照试验
BMJ. 2007 Jul 21;335(7611):142. doi: 10.1136/bmj.39224.494340.55. Epub 2007 Jun 7.
6
Infant serotonin transporter (SLC6A4) promoter genotype is associated with adverse neonatal outcomes after prenatal exposure to serotonin reuptake inhibitor medications.婴儿血清素转运体(SLC6A4)启动子基因型与产前暴露于血清素再摄取抑制剂药物后的不良新生儿结局相关。
Mol Psychiatry. 2008 Jan;13(1):65-73. doi: 10.1038/sj.mp.4002007. Epub 2007 May 22.
7
Therapeutic drug monitoring of quetiapine in adolescents with psychotic disorders.青少年精神病性障碍患者喹硫平的治疗药物监测
Pharmacopsychiatry. 2007 Mar;40(2):72-6. doi: 10.1055/s-2007-972573.
8
The EU-regulation on medicinal products for paediatric use: impacts on child and adolescent psychiatry and clinical research with minors.欧盟儿科用药品法规:对儿童和青少年精神病学以及未成年人临床研究的影响。
Eur Child Adolesc Psychiatry. 2007 Jun;16(4):229-35. doi: 10.1007/s00787-006-0594-8. Epub 2007 Apr 7.
9
Pharmacogenetics of morphine poisoning in a breastfed neonate of a codeine-prescribed mother.一位服用可待因母亲的母乳喂养新生儿吗啡中毒的药物遗传学
Lancet. 2006 Aug 19;368(9536):704. doi: 10.1016/S0140-6736(06)69255-6.
10
Antidepressant prevalence for youths: a multi-national comparison.青少年抗抑郁药的使用流行率:多国比较
Pharmacoepidemiol Drug Saf. 2006 Nov;15(11):793-8. doi: 10.1002/pds.1254.